Dr Mitchell Reff has joined ShangPharma as Chief Biologics Officer, bringing more than 30 years of research and development experience in the biopharmaceutical industry to the role.
Reff received his PhD in Medical Microbiology from Stanford University School of Medicine, and a degree in Chemistry from Massachusetts Institute of Technology. This was followed by a Postdoctoral Fellowship at Harvard Medical School and a position at the National Cancer Institute.
He then spent eight years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering. After that, he joined Idec Pharmaceuticals as head of molecular biology in 1990.
Reff had a distinguished 21-year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered six novel oncology drugs into clinical trials in five years.
